USANA HEALTH SCIENCES INC
USNANYSE
$21.82
↓ -3.7%Jul 17 close · end-of-day
Price
1Y↓ -30.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$401.7M
Enterprise Value
$239.0M
P/E
43.6
P/S
0.4
P/B
0.7
EV/EBITDA
3.5
PEG
—
FCF Yield
0.7%
Dividend Yield
—
Revenue (TTM)
$925.9M
Net Income (TTM)
$8.9M
Free Cash Flow (TTM)
$3.0M
Gross Margin
77.5%
Operating Margin
3.9%
Net Margin
1.0%
ROE
1.6%
ROIC
4.7%
Debt / Equity
—
Net Cash
$162.8M
Return 1Y
-28.8%
Company profile
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. USANA nutritional products comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups. Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups.
- CEO
- Kevin G. Guest
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,900
- Headquarters
- Utah
- Website
- usana.com
Earnings
USNA Q1 2026 Earnings
Period ends 2026-04-04
MetricActualYoY
Revenue$250.2M↑ +0.3%
Diluted EPS$0.41↓ -16.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.2B | $998.6M | $921.0M | $854.5M | $925.3M |
| Gross profit | $925.5M | $968.6M | $804.7M | $744.3M | $693.3M | $724.4M |
| Operating income | $176.5M | $170.2M | $107.6M | $93.1M | $66.3M | $37.4M |
| Net income | $124.7M | $116.5M | $69.3M | $63.8M | $42.0M | $10.8M |
| Diluted EPS | $5.86 | $5.73 | $3.59 | $3.30 | $2.19 | $0.58 |
| Operating cash flow | $160.4M | $121.2M | $103.9M | $70.6M | $61.0M | $22.3M |
| Free cash flow | $145.3M | $108.5M | $93.5M | $56.1M | $50.9M | $8.5M |
| Gross margin | 81.6% | 81.6% | 80.6% | 80.8% | 81.1% | 78.3% |
| Operating margin | 15.6% | 14.3% | 10.8% | 10.1% | 7.8% | 4.0% |
| Net margin | 11.0% | 9.8% | 6.9% | 6.9% | 4.9% | 1.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '26 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $212.9M | $200.2M | $213.6M | $249.5M | $235.8M | $213.7M | $226.2M | $250.2M |
| Gross profit | $172.5M | $161.0M | $175.1M | $197.1M | $185.7M | $164.9M | $176.8M | $190.8M |
| Operating income | $17.8M | $15.6M | $8.2M | $15.7M | $16.7M | $1.2M | $3.8M | $13.9M |
| Net income | $10.4M | $10.6M | $4.5M | $9.4M | $9.7M | -$6.5M | -$1.8M | $7.5M |
| Diluted EPS | $0.54 | $0.56 | $0.23 | $0.49 | $0.52 | -$0.36 | -$0.07 | $0.41 |
| Operating cash flow | $8.0M | $29.5M | $5.8M | $15.5M | $12.2M | -$2.0M | -$3.4M | $9.8M |
| Free cash flow | $5.3M | $27.1M | $4.0M | $12.7M | $7.2M | -$5.2M | -$6.2M | $7.1M |
| Gross margin | 81.1% | 80.4% | 82.0% | 79.0% | 78.7% | 77.2% | 78.2% | 76.2% |
| Operating margin | 8.4% | 7.8% | 3.8% | 6.3% | 7.1% | 0.6% | 1.7% | 5.5% |
| Net margin | 4.9% | 5.3% | 2.1% | 3.8% | 4.1% | -3.1% | -0.8% | 3.0% |
Company news
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.